Yes, we should assume the FDA will require some clinical trials for FoB's—i.e. knockoff drugs where the original brand was approved via a BLA rather than an NDA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”